Your browser doesn't support javascript.
loading
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics.
Richardson, Paul G; Schjesvold, Fredrik; Weisel, Katja; Moreau, Philippe; Anderson, Larry D; White, Darrell; Rodriguez-Otero, Paula; Sonneveld, Pieter; Engelhardt, Monika; Jenner, Matthew; Corso, Alessandro; Dürig, Jan; Pavic, Michel; Salomo, Morten; Beksac, Meral; Oriol, Albert; Lindsay, Jindriska; Liberati, Anna Marina; Galli, Monica; Robak, Pawel; Larocca, Alessandra; Yagci, Munci; Vural, Filiz; Kanate, Abraham S; Jiang, Ruiyun; Grote, Lara; Peluso, Teresa; Dimopoulos, Meletios.
Affiliation
  • Richardson PG; Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
  • Schjesvold F; Oslo Myeloma Center at Oslo University Hospital, KG Jebsen Center for B-Cell Malignancies, University of Oslo, Oslo, Norway.
  • Weisel K; Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Moreau P; University Hospital Hôtel-Dieu, Nantes, France.
  • Anderson LD; University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • White D; Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada.
  • Rodriguez-Otero P; Clinica Universidad de Navarra, CIMA, IDISNA, Pamplona, Spain.
  • Sonneveld P; Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • Engelhardt M; Universitätsklinikum Freiburg, Freiburg, Germany.
  • Jenner M; Southampton General Hospital, Southampton, UK.
  • Corso A; Policlinico San Matteo Universita Di Pavia, Pavia, Italy.
  • Dürig J; University Hospital Essen, Essen, Germany.
  • Pavic M; Centre Hospitalier Universitaire De Sherbrooke (CHUS), Centre de Recherche Clinique Etienne-Le Bel (CRCELB) Hopital Fleurimont, Sherbrooke, QC, Canada.
  • Salomo M; Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
  • Beksac M; Ankara University, Ankara, Turkey.
  • Oriol A; Institut Català d'Oncologia I Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona, Spain.
  • Lindsay J; East Kent Hospitals University NHS Foundation Trust, Kent and Canterbury Hospital, Canterbury, UK.
  • Liberati AM; University of Perugia, Perugia, Italy.
  • Galli M; Ospedale Papa Giovanni XXIII, U.O. di Ematologia, Ispedali Riuniti di Bergamo, Bergamo, Italy.
  • Robak P; Medical University of Lodz, Lodz, Poland.
  • Larocca A; A.O.U. Citta della Salute e della Scienza di Torino, Torino, Italy.
  • Yagci M; Gazi University Medical Faculty, Ankara, Turkey.
  • Vural F; Ege University, Izmir, Turkey.
  • Kanate AS; West Virginia University, Morgantown, West Virginia, USA.
  • Jiang R; Bristol Myers Squibb, Princeton, New Jersey, USA.
  • Grote L; Bristol Myers Squibb, Princeton, New Jersey, USA.
  • Peluso T; Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland.
  • Dimopoulos M; National and Kapodistrian University of Athens, Athens, Greece.
Eur J Haematol ; 108(1): 73-83, 2022 Jan.
Article in En | MEDLINE | ID: mdl-34496096
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Multiple Myeloma Type of study: Clinical_trials / Prognostic_studies Limits: Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Eur J Haematol Journal subject: HEMATOLOGIA Year: 2022 Type: Article Affiliation country: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Multiple Myeloma Type of study: Clinical_trials / Prognostic_studies Limits: Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Eur J Haematol Journal subject: HEMATOLOGIA Year: 2022 Type: Article Affiliation country: United States